CR20140047A - Dominios variables singulares anti-vgf fusionados con dominios de fc - Google Patents

Dominios variables singulares anti-vgf fusionados con dominios de fc

Info

Publication number
CR20140047A
CR20140047A CR20140047A CR20140047A CR20140047A CR 20140047 A CR20140047 A CR 20140047A CR 20140047 A CR20140047 A CR 20140047A CR 20140047 A CR20140047 A CR 20140047A CR 20140047 A CR20140047 A CR 20140047A
Authority
CR
Costa Rica
Prior art keywords
domains
antigen binding
vgf
dimers
fused
Prior art date
Application number
CR20140047A
Other languages
English (en)
Inventor
Claire Ashman
Ian Richard Catchpole
Zoe Hughes-Thomas
Alan Peter Lewis
Michael Steward
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46579044&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20140047(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CR20140047A publication Critical patent/CR20140047A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención está dirigida a construcciones de unión de antígeno que comprenden uno o dos dominios de unión de epítope separados por una región Fc de una sola cadena de un anticuerpo, en donde cada dominio de unión de epítope es capaz de unirse a VEGF; a dímeros que comprenden dos construcciones de unión de antígeno de la invención; composiciones farmacéuticas que comprenden dichos dímeros, y su uso en el tratamiento de enfermedades asociadas con la señalización de VEGF, tales como edema macular diabético (DME), degeneración macular húmeda asociada con la edad (AMD húmeda), retinopatía diabética, oclusión de la vena retinal (RVO) y neovascularización corneal; y secuencias de polinucleótido que codifican dichas construcciones de unión de antígeno.
CR20140047A 2011-07-27 2014-01-28 Dominios variables singulares anti-vgf fusionados con dominios de fc CR20140047A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161512138P 2011-07-27 2011-07-27

Publications (1)

Publication Number Publication Date
CR20140047A true CR20140047A (es) 2014-03-24

Family

ID=46579044

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20140047A CR20140047A (es) 2011-07-27 2014-01-28 Dominios variables singulares anti-vgf fusionados con dominios de fc

Country Status (19)

Country Link
US (2) US9499612B2 (es)
EP (1) EP2736925A2 (es)
JP (1) JP5987057B2 (es)
KR (1) KR101632620B1 (es)
CN (1) CN103842380A (es)
AU (1) AU2012288846B2 (es)
BR (1) BR112014001855A2 (es)
CA (1) CA2842099A1 (es)
CL (1) CL2014000204A1 (es)
CO (1) CO7020847A2 (es)
CR (1) CR20140047A (es)
DO (1) DOP2014000017A (es)
EA (1) EA028886B1 (es)
HK (1) HK1198446A1 (es)
MA (1) MA35352B1 (es)
MX (1) MX2014001019A (es)
PE (1) PE20141659A1 (es)
PH (1) PH12014500220A1 (es)
WO (1) WO2013014208A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
JP2014501725A (ja) * 2010-11-24 2014-01-23 グラクソ グループ リミテッド Ｈｇｆを標的とする多特異的抗原結合タンパク質
PH12022550313A1 (en) 2011-06-23 2023-01-23 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
CA2960297A1 (en) * 2014-11-10 2016-05-19 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
CA2978026A1 (en) 2015-03-11 2016-09-15 Glaxosmithkline Intellectual Property Development Limited Tslp binding proteins
BR112018013407A2 (en) 2015-12-30 2018-12-18 Kodiak Sciences Inc. antibodies and conjugates thereof
KR20180127344A (ko) * 2016-03-16 2018-11-28 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 단백질 A 결합 펩타이드, 항-EphA2 항체 및 이의 사용 방법
US20190119387A1 (en) 2016-04-05 2019-04-25 Glaxosmithkline Intellectual Property Development Limited Inhibition of tgfbeta in immunotherapy
EP3565595A4 (en) * 2017-01-06 2021-03-17 Momenta Pharmaceuticals, Inc. COMPOSITIONS AND METHODS ASSOCIATED WITH DOMAIN CONSTRUCTIONS OF BINDING TO MANIPULATED FC ANTIGEN
CN109021103B (zh) * 2017-06-12 2022-08-23 上海睿智化学研究有限公司 抗人血管内皮生长因子的抗体及其制备方法和应用
SG11202008242XA (en) 2018-03-02 2020-09-29 Kodiak Sciences Inc Il-6 antibodies and fusion constructs and conjugates thereof
EP3586860A1 (en) * 2018-06-22 2020-01-01 Universität Ulm Complement inhibitors and uses thereof
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
CA3174680A1 (en) 2020-03-13 2021-09-16 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
AR124917A1 (es) * 2021-02-19 2023-05-17 Dotbio Pte Ltd Moléculas de unión a vegfa
WO2023014892A1 (en) * 2021-08-04 2023-02-09 Alpine Biotherapeutics Corporation Sustainable ocular cell-mediated intraocular delivery of cellular therapeutics for treatment of ocular diseases or disorders
AU2022327397A1 (en) * 2021-08-13 2024-03-14 Innovent Biologics (Suzhou) Co., Ltd. Anti-vegf a and -vegf c bispecific antibody and use thereof
CN119677771A (zh) * 2022-08-02 2025-03-21 帕诺洛斯生物科技有限公司 经修饰的融合蛋白及其用途
WO2024055995A1 (zh) * 2022-09-14 2024-03-21 寻济生物科技（北京）有限公司 一种抗vegfa融合蛋白及其制备方法和应用
CN120025456B (zh) * 2024-03-13 2025-11-07 寻济生物科技（北京）有限公司 一种抗vegfa融合构建体及其制备方法和应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666884A (en) 1984-04-10 1987-05-19 New England Deaconess Hospital Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
EP0521985B1 (en) 1990-03-20 1997-09-24 The Trustees Of Columbia University In The City Of New York Chimeric antibodies with receptor binding ligands in place of their constant region
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1993022332A2 (en) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5747035A (en) 1995-04-14 1998-05-05 Genentech, Inc. Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
US5702892A (en) 1995-05-09 1997-12-30 The United States Of America As Represented By The Department Of Health And Human Services Phage-display of immunoglobulin heavy chain libraries
WO1997043316A1 (en) 1996-05-10 1997-11-20 Beth Israel Deaconess Medical Center, Inc. Physiologically active molecules with extended half-lives and methods of using same
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
PL199659B1 (pl) 1998-02-25 2008-10-31 Merck Patent Gmbh Białko fuzyjne przeciwciała hu-KS IL2, cząsteczka DNA kodująca białko fuzyjne przeciwciała hu-KS IL2 i sposób wytwarzania białka fuzyjnego przeciwciała hu-KS IL2
ES2299244T3 (es) 1998-05-13 2008-05-16 Domantis Limited Sistema de exposicion de fagos para la seleccion de proteinas correctamente plegadas.
US20020142374A1 (en) 1998-08-17 2002-10-03 Michael Gallo Generation of modified molecules with increased serum half-lives
IL127127A0 (en) * 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
KR101077001B1 (ko) 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
AU7950400A (en) 1999-10-19 2001-04-30 Kyowa Hakko Kogyo Co. Ltd. Process for producing polypeptide
JP2003523742A (ja) 2000-02-03 2003-08-12 ドマンティス リミテッド コンビナトリアルタンパク質ドメイン
US6374470B1 (en) 2000-10-06 2002-04-23 Milliken & Company Face plate for spun-like textured yarn
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
RU2321630C2 (ru) 2001-08-03 2008-04-10 Гликарт Биотекнолоджи АГ Гликозилированные антитела (варианты), обладающие повышенной антителозависимой клеточной цитотоксичностью
US7696320B2 (en) * 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
CN101039959A (zh) * 2004-06-30 2007-09-19 杜门蒂斯有限公司 用于治疗炎性疾病的组合物和方法
AU2005269759A1 (en) 2004-07-21 2006-02-09 Glycofi, Inc. Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
UA94213C2 (ru) * 2004-09-17 2011-04-26 Домантис Лимитед Применение полипептида одноцепочечного антитела, который подавляет активность cd40 или cd40l в приготовлении медикамента для лечения аутоиммунного заболевания
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
US7923538B2 (en) 2005-07-22 2011-04-12 Kyowa Hakko Kirin Co., Ltd Recombinant antibody composition
EP1921090B1 (en) 2005-07-22 2015-01-14 Kyowa Hakko Kirin Co., Ltd. Genetically modified antibody composition
KR20100021601A (ko) * 2007-05-14 2010-02-25 바이오겐 아이덱 엠에이 인코포레이티드 단일-쇄 Ｆｃ(ＳｃＦｃ) 부분, 이를 포함하는 결합 폴리펩타이드, 및 이에 관련된 방법
GB0724331D0 (en) * 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
EA200901494A1 (ru) * 2007-06-06 2010-06-30 Домантис Лимитед Способы селекции протеазоустойчивых полипептидов
EP2641919A3 (en) 2007-11-30 2014-05-07 Glaxo Group Limited Antigen-binding constructs
US20100260853A1 (en) * 2007-12-13 2010-10-14 Amrik Basran Compositions for pulmonary delivery
SI2235064T1 (sl) * 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
CA2753287A1 (en) * 2009-02-24 2010-09-02 Glaxo Group Limited Antigen-binding constructs
US20120076787A1 (en) * 2009-05-28 2012-03-29 Peter Adamson Combination of a tnf-alpha antagonist and a vegf antagonist for use in the treatment or prevention of diseases of the eye
US8703132B2 (en) * 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
AU2010321720B2 (en) * 2009-11-23 2017-03-02 Amgen Inc. Monomeric antibody Fc
JP2014501725A (ja) * 2010-11-24 2014-01-23 グラクソ グループ リミテッド Ｈｇｆを標的とする多特異的抗原結合タンパク質
JP2014505698A (ja) * 2011-02-02 2014-03-06 グラクソ グループ リミテッド 新規抗原結合タンパク質

Also Published As

Publication number Publication date
MX2014001019A (es) 2014-05-13
DOP2014000017A (es) 2014-04-30
PE20141659A1 (es) 2014-11-21
PH12014500220A1 (en) 2019-03-22
WO2013014208A3 (en) 2013-05-10
US9499612B2 (en) 2016-11-22
AU2012288846B2 (en) 2016-05-19
EA201391812A1 (ru) 2014-06-30
MA35352B1 (fr) 2014-08-01
EA028886B1 (ru) 2018-01-31
CO7020847A2 (es) 2014-08-11
JP5987057B2 (ja) 2016-09-06
JP2014523746A (ja) 2014-09-18
HK1198446A1 (en) 2015-04-24
US20140205604A1 (en) 2014-07-24
KR101632620B1 (ko) 2016-06-23
US20170029494A1 (en) 2017-02-02
KR20140041908A (ko) 2014-04-04
CL2014000204A1 (es) 2014-07-25
EP2736925A2 (en) 2014-06-04
CA2842099A1 (en) 2013-01-31
CN103842380A (zh) 2014-06-04
WO2013014208A2 (en) 2013-01-31
AU2012288846A1 (en) 2014-02-06
BR112014001855A2 (pt) 2017-02-21

Similar Documents

Publication Publication Date Title
CR20140047A (es) Dominios variables singulares anti-vgf fusionados con dominios de fc
MX347226B (es) Tratamiento de enfermedad ocular.
EA201500132A1 (ru) Биспецифические антитела к vegf/ang-2 и их применение для лечения сосудистых глазных заболеваний
UY36302A (es) Proteína de unión a antígenos, bi-específicos del receptor anti-cgrp/receptor pac1 y usos de las mismas
MX2017005977A (es) Anticuerpos biespecificos y metodos de uso en oftalmologia.
CY1120213T1 (el) Antαγωνιστες φθοριωμενης ιντεγκρινης
ECSP13012712A (es) Mutantes fc de anticuerpos resistentes a proteasas activas
EA201690633A1 (ru) Способы и композиции, включающие комбинацию антагониста vegf и анти-ctla-4 антитела
MX2015005831A (es) Antagonistas de il-6 y usos de los mismos.
MX374929B (es) RECEPTOR QUIMERICO DE ANTIGENO anti-EGFRvlll HUMANIZADO Y USOS DEL MISMO.
UA112743C2 (uk) Терапевтичний dll4-зв'язувальний білок
BR112017009807A2 (pt) métodos e formulações para tratamento de doenças oculares vasculares
GT201500100A (es) Inmunoglobulinas de dominio variable dual anti-vegf/dll4 y usos de las mismas
ECSP13013001A (es) Moléculas de unión biespecíficas que se unen a vegf y ang2.
EA201391611A1 (ru) Вызывающие иммунную толерантность синтетические наноносители для терапевтического лечения аллергии
BR112016020377A2 (pt) proteínas fc multiméricas
EA201300137A1 (ru) Комбинированная фармацевтическая композиция и способ лечения заболеваний или состояний, связанных с нейродегенеративными зоболеваниями
EA201791005A1 (ru) Улучшенные антитела против il-6
EA201500371A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМБИНАЦИИ, СОДЕРЖАЩИЕ ДВОЙНЫЕ АНГИПОЭТИН-2/Dll4 СВЯЗЫВАЮЩИЕ АГЕНТЫ И АНТИ-VEGF АГЕНТЫ
AR100978A1 (es) LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
MA40182A (fr) NOUVEL ANTICORPS ANTI-Tie2 HUMAIN
UA118674C2 (uk) Антитіло до igf-1r з елімінованою здатністю зв'язуватися з fcrn та його застосування для лікування судинних захворювань очей
MX2015008534A (es) COMPOSICIONES DE ANTICUERPO ANTI-INTEGRINA ß1 Y METODOS DE USO DE LAS MISMAS.
ECSP13012996A (es) Moléculas de unión biespecíficas que se unen a dll4 y ang2.
EA201691400A1 (ru) Опсин-связывающие лиганды, композиции и способы их использования